Patient characteristics and posttransplant outcomes
| Patient no. . | Age/sex . | Prior BV . | Pre-HCT disease status . | Donor . | Acute GVHD grade . | Chronic GVHD . | Relapsed . | Salvage therapy after relapse . | Status at last follow-up . | Follow-up days post-HCT . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 27/M | No | CR | MRD | None | None | No | — | Alive in CR | 1559 |
| 2 | 36/F | No | CR | MUD | None | None | No | — | Alive in CR | 2163 |
| 3 | 24/F | No | CR | MUD | 3 | Mild | No | — | Alive in CR | 2188 |
| 4 | 48/F | No | CR | MUD | None | None | No | — | Alive in CR | 1433 |
| 5 | 44/M | Yes | CR | MUD | None | None | No | — | Alive in CR | 768 |
| 6 | 24/F | No | CR | MUD | 1 | None | No | — | Dead in CR | 535 |
| 7 | 34/M | No | PR | MMUD | 1 | Mild | No | — | Alive in CR | 2540 |
| 8 | 25/F | No | PR | MRD | 1 | None | No | — | Alive in CR | 1468 |
| 9 | 37/F | Yes | PR | MUD | 1 | Mild | No | — | Alive in CR | 1603 |
| 10 | 22/F | Yes | PR | MMUD | None | Mild | No | — | Alive in CR | 1125 |
| 11 | 42/F | Yes | PR | MRD | None | None | No | — | Alive in CR | 663 |
| 12 | 27/F | Yes | PR | MMUD | 2 | None | No | — | Alive in CR | 313 |
| 13 | 42/F | Yes | PR | MRD | None | Mild | No | — | Alive in CR | 1435 |
| 14 | 26/M | Yes | PR | MMUD | None | Moderate | No | — | Alive in CR | 801 |
| 15 | 22/M | No | SD | MRD | None | None | No | — | Alive in CR | 2262 |
| 16 | 21/F | No | SD | MMUD | 1 | Moderate | No | — | Alive in CR | 1387 |
| 17 | 27/M | Yes | PD | MUD | None | Mild | No | — | Alive in CR | 1506 |
| 18 | 46/F | No | CR | MRD | None | None | Day +523 | C-MOPP, DLI | Alive in CR | 2852 |
| 19 | 43/M | Yes | CR | MMUD | 1 | None | Day +749 | Bendamustine, DLI | Alive in CR | 2513 |
| 20 | 26/F | No | CR | MUD | None | Moderate | Day +96 | RT (local relapse) | Alive in CR | 2901 |
| 21 | 30/M | Yes | CR | MRD | 1 | Mild | Day +791 | RT (local relapse) | Alive in CR | 1449 |
| 22 | 23/M | No | CR | MUD | None | None | Day +1242 | BV | Alive with PD | 2560 |
| 23 | 51/M | Yes | CR | MMUD | 1 | None | Day +355 | BV, bendamustine | Alive with PD | 753 |
| 24 | 39/M | No | CR | MMUD | 1 | None | Day +742 | BV | Dead with PD | 843 |
| 25 | 26/F | Yes | CR | MRD | None | Mild | Day +201 | BV | Dead with PD | 420 |
| 26 | 25/M | No | PR | MRD | None | None | Day +490 | BV | Alive in CR | 1747 |
| 27 | 32/F | No | PR | MMUD | None | None | Day +144 | Nivolumab | Alive in CR | 1109 |
| 28 | 37/F | Yes | PR | MRD | 2 | Moderate | Day +321 | Bendamustine | Alive with PR | 500 |
| 29 | 28/F | No | PR | MRD | None | Moderate | Day +320 | Gemcitabine, DLI | Alive with PR | 3605 |
| 30 | 37/M | No | PR | MRD | None | Moderate | Day +284 | DLI | Dead with PD | 779 |
| 31 | 26/M | No | PR | MRD | 2 | Mild | Day +406 | ESHAP, DLI, BV | Dead with PD | 1658 |
| 32 | 29/M | No | PR | MRD | None | None | Day +216 | BV | Dead with PD | 1179 |
| 33 | 24/M | Yes | PR | MUD | None | None | Day +306 | Lenalidomide, RT | Dead with PD | 587 |
| Patient no. . | Age/sex . | Prior BV . | Pre-HCT disease status . | Donor . | Acute GVHD grade . | Chronic GVHD . | Relapsed . | Salvage therapy after relapse . | Status at last follow-up . | Follow-up days post-HCT . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 27/M | No | CR | MRD | None | None | No | — | Alive in CR | 1559 |
| 2 | 36/F | No | CR | MUD | None | None | No | — | Alive in CR | 2163 |
| 3 | 24/F | No | CR | MUD | 3 | Mild | No | — | Alive in CR | 2188 |
| 4 | 48/F | No | CR | MUD | None | None | No | — | Alive in CR | 1433 |
| 5 | 44/M | Yes | CR | MUD | None | None | No | — | Alive in CR | 768 |
| 6 | 24/F | No | CR | MUD | 1 | None | No | — | Dead in CR | 535 |
| 7 | 34/M | No | PR | MMUD | 1 | Mild | No | — | Alive in CR | 2540 |
| 8 | 25/F | No | PR | MRD | 1 | None | No | — | Alive in CR | 1468 |
| 9 | 37/F | Yes | PR | MUD | 1 | Mild | No | — | Alive in CR | 1603 |
| 10 | 22/F | Yes | PR | MMUD | None | Mild | No | — | Alive in CR | 1125 |
| 11 | 42/F | Yes | PR | MRD | None | None | No | — | Alive in CR | 663 |
| 12 | 27/F | Yes | PR | MMUD | 2 | None | No | — | Alive in CR | 313 |
| 13 | 42/F | Yes | PR | MRD | None | Mild | No | — | Alive in CR | 1435 |
| 14 | 26/M | Yes | PR | MMUD | None | Moderate | No | — | Alive in CR | 801 |
| 15 | 22/M | No | SD | MRD | None | None | No | — | Alive in CR | 2262 |
| 16 | 21/F | No | SD | MMUD | 1 | Moderate | No | — | Alive in CR | 1387 |
| 17 | 27/M | Yes | PD | MUD | None | Mild | No | — | Alive in CR | 1506 |
| 18 | 46/F | No | CR | MRD | None | None | Day +523 | C-MOPP, DLI | Alive in CR | 2852 |
| 19 | 43/M | Yes | CR | MMUD | 1 | None | Day +749 | Bendamustine, DLI | Alive in CR | 2513 |
| 20 | 26/F | No | CR | MUD | None | Moderate | Day +96 | RT (local relapse) | Alive in CR | 2901 |
| 21 | 30/M | Yes | CR | MRD | 1 | Mild | Day +791 | RT (local relapse) | Alive in CR | 1449 |
| 22 | 23/M | No | CR | MUD | None | None | Day +1242 | BV | Alive with PD | 2560 |
| 23 | 51/M | Yes | CR | MMUD | 1 | None | Day +355 | BV, bendamustine | Alive with PD | 753 |
| 24 | 39/M | No | CR | MMUD | 1 | None | Day +742 | BV | Dead with PD | 843 |
| 25 | 26/F | Yes | CR | MRD | None | Mild | Day +201 | BV | Dead with PD | 420 |
| 26 | 25/M | No | PR | MRD | None | None | Day +490 | BV | Alive in CR | 1747 |
| 27 | 32/F | No | PR | MMUD | None | None | Day +144 | Nivolumab | Alive in CR | 1109 |
| 28 | 37/F | Yes | PR | MRD | 2 | Moderate | Day +321 | Bendamustine | Alive with PR | 500 |
| 29 | 28/F | No | PR | MRD | None | Moderate | Day +320 | Gemcitabine, DLI | Alive with PR | 3605 |
| 30 | 37/M | No | PR | MRD | None | Moderate | Day +284 | DLI | Dead with PD | 779 |
| 31 | 26/M | No | PR | MRD | 2 | Mild | Day +406 | ESHAP, DLI, BV | Dead with PD | 1658 |
| 32 | 29/M | No | PR | MRD | None | None | Day +216 | BV | Dead with PD | 1179 |
| 33 | 24/M | Yes | PR | MUD | None | None | Day +306 | Lenalidomide, RT | Dead with PD | 587 |
BV, brentuximab vedotin; C-MOPP, cyclophosphamide, vincristine, procarbazine, prednisone; DLI, donor lymphocyte infusion; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; F, female; M, male; MRD, matched related donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease.